Maryland's COVID-19 Vaccine Adjusts Guidance

Gaithersburg, MD-based Novavax Inc. recently announced adjusted financial guidance for 2022 to account for several evolving market dynamics. For the second quarter of 2022, total company revenue of $186 million included $78 million of product sales/royalties from the protein-based COVID-19 vaccine (NVX-CoV2373).

And the company revised the full year 2022 total revenue guidance to $2 to $2.3 billion.

'We remain confident in our (COVID-19) vaccine as a strong additional choice,' stated Novavax on August 8, 2022.

'We have built a global presence with authorizations (Nuvaxovid or Covovax) in 43 countries and Emergency Use Listing with the WHO.

In the U.S., 'we have successfully brought our vaccine to market under U.S. FDA Emergency Use Authorization, and vaccinations are now underway in 47 states.'

'Its competitive product profile includes our vaccine's efficacy, well-tolerated safety profile, the durability of protection, and ability to address both current and future variant strains,' stated the company on August 8, 2022.

'In Q32022, we are already making tremendous progress. We have shipped over 23 million COVID-19 vaccine doses since the beginning of July 2022.'

'Overall, we remain committed to developing new first-in-class vaccine candidates with the potential to address today's most urgent global health needs, including both our COVID-19-Influenza combination and a stand-alone influenza vaccine expected to be in Phase 3 next year (2023),' concluded the company's statement.

Note: Novavax's statements were manually curated for mobile readers.